In situ glucosylceramide synthesis and its pharmacological inhibition analysed in cells by 13 C5 -sphingosine precursor feeding and mass spectrometry

FEBS Lett. 2022 Sep;596(18):2400-2408. doi: 10.1002/1873-3468.14448. Epub 2022 Jul 13.

Abstract

Glycosphingolipids (GSLs) fulfil diverse functions in cells. Abnormalities in their metabolism are associated with specific pathologies and, consequently, the pharmacological modulation of GSLs is considered a therapeutic avenue. The accurate measurement of in situ metabolism of GSLs and the modulatory impact of drugs is warranted. Employing synthesised sphingosine and sphinganine containing 13 C atoms, we developed a method to monitor the de novo synthesis of glucosylceramide, the precursor of complex GSLs, by the enzyme glucosylceramide synthase (GCS). We show that feeding cells with isotope-labelled precursor combined with liquid chromatography-mass spectrometry (MS)/MS analysis allows accurate determination of the IC50 values of therapeutically considered inhibitors (iminosugars and ceramide mimics) of GCS in cultured cells. Acquired data were comparable to those obtained with an earlier method using artificial fluorescently labelled ceramide to feed cells.

Keywords: 13C-labelled lipids; glucosylceramide synthase; glycosphingolipid metabolism; mass spectrometry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ceramides / metabolism
  • Glucosylceramides* / metabolism
  • Glycosphingolipids / metabolism
  • Mass Spectrometry
  • Sphingosine* / pharmacology

Substances

  • Ceramides
  • Glucosylceramides
  • Glycosphingolipids
  • Sphingosine